UA79457C2 - Association of antithrombotic agent with aspirin and pharmaceutical composition for treating atherothrombotic diseases - Google Patents
Association of antithrombotic agent with aspirin and pharmaceutical composition for treating atherothrombotic diseases Download PDFInfo
- Publication number
- UA79457C2 UA79457C2 UA20041109009A UA20041109009A UA79457C2 UA 79457 C2 UA79457 C2 UA 79457C2 UA 20041109009 A UA20041109009 A UA 20041109009A UA 20041109009 A UA20041109009 A UA 20041109009A UA 79457 C2 UA79457 C2 UA 79457C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compound
- aspirin
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 9
- 201000010099 disease Diseases 0.000 title claims description 6
- 239000003146 anticoagulant agent Substances 0.000 title abstract description 4
- 229960004676 antithrombotic agent Drugs 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 5
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150116749 chuk gene Proteins 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002442 hydroxyeicosatetraenoic acids Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002535 isoprostanes Chemical class 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- -1 thromboxane A 25 Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0204222A FR2838057B1 (fr) | 2002-04-05 | 2002-04-05 | Nouvelle association d'un antithrombotique et d'aspirine |
| PCT/FR2003/001054 WO2003084525A1 (fr) | 2002-04-05 | 2003-04-04 | Nouvelle association d'un antithrombotique et d'aspirine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA79457C2 true UA79457C2 (en) | 2007-06-25 |
Family
ID=28052120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20041109009A UA79457C2 (en) | 2002-04-05 | 2003-04-04 | Association of antithrombotic agent with aspirin and pharmaceutical composition for treating atherothrombotic diseases |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7618955B2 (no) |
| EP (1) | EP1496884B1 (no) |
| JP (1) | JP4065853B2 (no) |
| KR (1) | KR100645143B1 (no) |
| CN (1) | CN1297265C (no) |
| AR (1) | AR039253A1 (no) |
| AT (1) | ATE329591T1 (no) |
| AU (1) | AU2003246774B2 (no) |
| BR (1) | BR0309019A (no) |
| CA (1) | CA2480697A1 (no) |
| CY (1) | CY1105106T1 (no) |
| DE (1) | DE60306133T2 (no) |
| DK (1) | DK1496884T3 (no) |
| EA (1) | EA006978B1 (no) |
| ES (1) | ES2264533T3 (no) |
| FR (1) | FR2838057B1 (no) |
| GE (1) | GEP20074101B (no) |
| HK (1) | HK1076034A1 (no) |
| MA (1) | MA27114A1 (no) |
| MX (1) | MXPA04009760A (no) |
| NO (1) | NO20044700L (no) |
| NZ (1) | NZ535430A (no) |
| PL (1) | PL371620A1 (no) |
| PT (1) | PT1496884E (no) |
| UA (1) | UA79457C2 (no) |
| WO (1) | WO2003084525A1 (no) |
| ZA (1) | ZA200407593B (no) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080017489A (ko) * | 2005-07-22 | 2008-02-26 | 더 프록터 앤드 갬블 캄파니 | 약물 유발성 부정맥 발생률 감소용 조성물 |
| CN103071154A (zh) | 2007-04-13 | 2013-05-01 | 千年药品公司 | 用起因子xa抑制剂作用的化合物的组合抗凝治疗 |
| JP2009001537A (ja) * | 2007-06-25 | 2009-01-08 | Lab Servier | 血管障害の処置を目的とする医薬の入手における抗アテローム血栓化合物の使用 |
| FR2920772B1 (fr) * | 2007-09-11 | 2009-10-23 | Servier Lab | Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2711139B1 (fr) * | 1993-10-15 | 1995-12-01 | Adir | Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
-
2002
- 2002-04-05 FR FR0204222A patent/FR2838057B1/fr not_active Expired - Fee Related
-
2003
- 2003-04-04 CN CNB038078619A patent/CN1297265C/zh not_active Expired - Fee Related
- 2003-04-04 MX MXPA04009760A patent/MXPA04009760A/es active IP Right Grant
- 2003-04-04 EP EP03745819A patent/EP1496884B1/fr not_active Expired - Lifetime
- 2003-04-04 BR BR0309019-1A patent/BR0309019A/pt not_active IP Right Cessation
- 2003-04-04 NZ NZ535430A patent/NZ535430A/en unknown
- 2003-04-04 DK DK03745819T patent/DK1496884T3/da active
- 2003-04-04 KR KR1020047015845A patent/KR100645143B1/ko not_active IP Right Cessation
- 2003-04-04 UA UA20041109009A patent/UA79457C2/uk unknown
- 2003-04-04 CA CA002480697A patent/CA2480697A1/fr not_active Abandoned
- 2003-04-04 US US10/509,605 patent/US7618955B2/en not_active Expired - Fee Related
- 2003-04-04 DE DE60306133T patent/DE60306133T2/de not_active Expired - Fee Related
- 2003-04-04 AR ARP030101180A patent/AR039253A1/es unknown
- 2003-04-04 EA EA200401293A patent/EA006978B1/ru not_active IP Right Cessation
- 2003-04-04 WO PCT/FR2003/001054 patent/WO2003084525A1/fr active IP Right Grant
- 2003-04-04 ES ES03745819T patent/ES2264533T3/es not_active Expired - Lifetime
- 2003-04-04 PL PL03371620A patent/PL371620A1/xx not_active Application Discontinuation
- 2003-04-04 PT PT03745819T patent/PT1496884E/pt unknown
- 2003-04-04 JP JP2003581765A patent/JP4065853B2/ja not_active Expired - Fee Related
- 2003-04-04 AT AT03745819T patent/ATE329591T1/de not_active IP Right Cessation
- 2003-04-04 GE GEAP8486A patent/GEP20074101B/en unknown
- 2003-04-04 AU AU2003246774A patent/AU2003246774B2/en not_active Ceased
-
2004
- 2004-09-21 ZA ZA200407593A patent/ZA200407593B/xx unknown
- 2004-10-29 NO NO20044700A patent/NO20044700L/no not_active Application Discontinuation
- 2004-11-03 MA MA27925A patent/MA27114A1/fr unknown
-
2005
- 2005-09-16 HK HK05108135A patent/HK1076034A1/xx not_active IP Right Cessation
-
2006
- 2006-07-24 CY CY20061101027T patent/CY1105106T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4826875A (en) | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof | |
| JPS629103B2 (no) | ||
| JP2009543872A (ja) | 選択的アンドロゲン受容体調節薬、その類似体及び誘導体とそれらの使用 | |
| JPH04346927A (ja) | 脳内グルタミン酸遊離抑制剤 | |
| UA79457C2 (en) | Association of antithrombotic agent with aspirin and pharmaceutical composition for treating atherothrombotic diseases | |
| JP2021530488A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| JP3363440B2 (ja) | 脊髄小脳変性症治療剤および脊髄小脳変性症治療用組成物 | |
| US4086354A (en) | Novel anti-hypertensive compositions | |
| JP2005528376A5 (no) | ||
| JPH0152366B2 (no) | ||
| US3883656A (en) | Pharmaceutical preparations for the treatment of hypertonia | |
| JP2018515507A5 (no) | ||
| EA009418B1 (ru) | Комбинация антиатеротромботического средства и средства, предотвращающего агрегацию тромбоцитов | |
| JPH10101556A (ja) | ファクターｄ阻害剤 | |
| JPS58164507A (ja) | ジベンゾシクロヘプテニリデン類による免疫変化剤 | |
| US3944671A (en) | Treatment of adrenal malfunction | |
| KR20190035724A (ko) | N,n-비스-2-메르캅토에틸 이소프탈아미드의 용도 | |
| WO2018012634A1 (ja) | 不飽和複素５員環含有化合物を含有する肺高血圧症の予防又は治療剤 | |
| EP1135122B1 (en) | Use of amtolmetin guacyl as for the treatment of intestinal inflammations | |
| JPH0336821B2 (no) | ||
| HU208424B (en) | Process for producing new cyclicantranyl-acetic acid derivatives salts with acids and bases and pharmaceutical compositions containing them as active components | |
| FR2832929A1 (fr) | Compositions pharmaceutiques contenant un agent antithrombotique et un derive d'amines cycliques |